AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Director Mark G. Edwards purchased 5,000 shares of the stock in a transaction dated Thursday, August 24th. The stock was acquired at an average cost of $3.02 per share, for a total transaction of $15,100.00. Following the completion of the transaction, the director now owns 115,200 shares of the company’s stock, valued at approximately $347,904. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ ACRX) traded down 0.84% during midday trading on Friday, hitting $2.95. The stock had a trading volume of 1,136,886 shares. The company’s 50 day moving average price is $2.99 and its 200-day moving average price is $2.80. The firm’s market capitalization is $133.87 million. AcelRx Pharmaceuticals, Inc. has a 1-year low of $1.95 and a 1-year high of $4.08.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.01. AcelRx Pharmaceuticals had a negative net margin of 319.19% and a negative return on equity of 478.66%. The business had revenue of $2.66 million during the quarter, compared to the consensus estimate of $2.63 million. Equities analysts predict that AcelRx Pharmaceuticals, Inc. will post ($1.13) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/27/acelrx-pharmaceuticals-inc-acrx-director-buys-15100-00-in-stock.html.

Hedge funds have recently bought and sold shares of the stock. ING Groep NV raised its stake in AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock valued at $123,000 after buying an additional 26,000 shares during the period. Acadian Asset Management LLC raised its stake in AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 32,087 shares during the period. Teachers Advisors LLC raised its stake in AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 8,475 shares during the period. Virtu KCG Holdings LLC raised its stake in AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 101,742 shares during the period. Finally, LMR Partners LLP acquired a new stake in AcelRx Pharmaceuticals during the second quarter valued at about $319,000. 30.37% of the stock is currently owned by institutional investors.

Several brokerages have recently issued reports on ACRX. Cowen and Company reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Tuesday, August 1st. Roth Capital reaffirmed a “buy” rating and issued a $12.50 price target on shares of AcelRx Pharmaceuticals in a research report on Thursday, August 10th. Zacks Investment Research raised AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Royal Bank Of Canada set a $6.00 price target on AcelRx Pharmaceuticals and gave the company a “buy” rating in a research report on Friday. Finally, ValuEngine downgraded AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $7.50.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Receive News & Stock Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.